Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:

NCT ID: NCT04425824 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Start date: June 15, 2020
Phase: Phase 2
Study type: Interventional

Exploring the efficacy and safety of Toripalimab with Rituximab for treatment of relapsed refractory CD20 positive diffuse large B-cell lymphoma.

NCT ID: NCT04419909 Not yet recruiting - Lymphoma, B-Cell Clinical Trials

Retreatment With CTL019/CTL119

Start date: May 2024
Phase: Phase 1
Study type: Interventional

This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.

NCT ID: NCT04412174 Not yet recruiting - Clinical trials for B-cell Non Hodgkin Lymphoma

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

Start date: June 2020
Phase: Early Phase 1
Study type: Interventional

The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-NHL. The investigators plan to include 18 subjects to receive GC022F therapy.

NCT ID: NCT04303247 Not yet recruiting - Clinical trials for B-cell Lymphoma Refractory

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Start date: May 1, 2020
Phase: Early Phase 1
Study type: Interventional

Although the anti-CD19 CAR-T cell therapies have gained significant results in patients with relapsed and refractory B-cell hematologic malignancies. There are patients who resisted anti-CD19 CAR-T cells or with CD19 negative relapse. To make further improvement, combining CD19 and CD22 as dual-targets for CAR-T cells, which adapt the FasT CAR-T cells manufacture technology to shorten the manufacture time and maintain the stemness of CAR-T cells. We launch such a clinical trial using CD19 and CD22 targeted CAR-T cells for patients with relapsed and refractory B-cell NHL to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cell therapy.

NCT ID: NCT04237168 Not yet recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)

Start date: January 2020
Phase:
Study type: Observational

This study will evaluate IgNGS at different time points in newly diagnosed DLBCL patients homogeneously treated (RCHOP) to address its correlation with conventional techniques (i.e., positron emission tomography/computed tomography imaging (PET/CT) and outcome.

NCT ID: NCT04056975 Not yet recruiting - Clinical trials for Relapsed or Refractory B-cell Lymphoma

Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

A-319
Start date: September 15, 2019
Phase: Phase 1
Study type: Interventional

Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma

NCT ID: NCT04026100 Not yet recruiting - Clinical trials for Diffuse Large B-cell Lymphoma

CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma

Start date: December 1, 2019
Phase: Phase 1
Study type: Interventional

This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.

NCT ID: NCT04023916 Not yet recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Start date: December 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Sintilimab and R-CHOP regimen as the first-line treatment for DLBCL patients with TP53 mutation and PD-L1 positive.

NCT ID: NCT03824964 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

NCT ID: NCT03824951 Not yet recruiting - Clinical trials for Refractory B-Cell Lymphoma

Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Start date: February 1, 2019
Phase: Early Phase 1
Study type: Interventional

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19 iCAR NK cells in patients with relapsed refractory B cell lymphoma.